INSIGHTS ON ENTERPRISE SOLUTIONS

• Aligning Scientific Expertise To Accelerate Complex Biologics Programs

  Complex biologics often outgrow traditional development platforms. Learn how an integrated development strategy can accelerate timelines while reducing risk.

• CLD Case Study: Complex Biologics – Bispecific Fusion Nanobody

  See how a bispecific fusion nanobody (BFN) achieved BsAb titers above 7 g/L with 5 of 6 clones stable beyond 60 generations — from CLD through cGMP manufacturing.

• Inside GRAM's Modern Fill-Finish Technology For Biologics

  Emerging fill-finish technologies improve sterility, quality control, and flexibility while enabling prefilled systems and biologics scale-up.

• Starting With The End In Mind

  Complex biologics need scalable, GMP-ready development from the start. Early decisions, scientific continuity, and strong partnerships help reduce delays and rework.

• When To Conduct GMP Versus Non-GMP Stability Studies — And Why Both Matter

  7/15/2026

  Understanding when to leverage GMP vs non-GMP stability studies and where each approach delivers maximum value can help sponsors make better development decisions and reach clinic faster.

• Modular vs Flexible Aseptic Filling Lines: Impacts On Speed, Changeovers, And Scale

  7/10/2026

  Modular suites with built-in contamination control streamline sterile manufacturing—supporting complex products, faster timelines, greater flexibility, less disruption, and scalable fill‑finish.

• Negative Stain TEM For Viral Particle Characterization

  7/8/2026

  Standardized latex bead references combined with negative stain TEM provide precise viral particle characterization and consistent viral load quantification.

• Lyophilization Excellence: Partnering For Sterile Fill/Finish Success

  7/8/2026

  As complex therapies continue to evolve, advanced lyophilization approaches can help improve stability, consistency, scalability, and product quality.